Back to Search
Start Over
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Dec 06; Vol. 12, pp. 789473. Date of Electronic Publication: 2021 Dec 06 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Competing Interests: LB has participated in an advisory board to Incyte Inc. on epacadostat in melanoma and was invited to give a MSL seminar to Incyte Inc. on IDO (2017). GP declares a conflict of interest due to his role as a co-inventor in the discovery and development of IDO/TDO inhibitor technologies patented by the Lankenau Institute for Medical Research and licensed to Duet Therapeutics, Inc., a private company for which he serves presently as a scientific advisor. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Subjects :
- Animals
Antineoplastic Agents adverse effects
Enzyme Inhibitors adverse effects
Humans
Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism
Molecular Targeted Therapy
Neoplasms enzymology
Neoplasms immunology
Signal Transduction
Tryptophan Oxygenase metabolism
Tumor Escape drug effects
Tumor Microenvironment
Antineoplastic Agents therapeutic use
Enzyme Inhibitors therapeutic use
Immunotherapy adverse effects
Indoleamine-Pyrrole 2,3,-Dioxygenase antagonists & inhibitors
Neoplasms drug therapy
Tryptophan Oxygenase antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 34938297
- Full Text :
- https://doi.org/10.3389/fimmu.2021.789473